Inhibition of ۵-Lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model

Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 221

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-20-11_005

تاریخ نمایه سازی: 28 مهر 1400

Abstract:

Objective(s): Arachidonic Acid/۵-lipoxygenase (AA/۵-LOX) pathway connects lipid metabolism and proinflammatory cytokine, which are both related to the development and progression of nonalcoholic fatty liver disease (NAFLD). Therefore, the present study was designed to investigate the role of AA/۵-LOX pathway in progression of NAFLD, and the effect of zileuton, an inhibitor of ۵-LOX, in this model. Materials and Methods: Animal model for progression of NAFLD was established via feeding high saturated fat diet (HFD). Liver function, HE staining, NAFLD activity score (NAS) were used to evaluate NAFLD progression. We detected the lipid metabolism substrates: free fatty acids (FFA) and AA, products: cysteinyl-leukotrienes (CysLTs), and changes in gene and protein level of key enzyme in AA/۵-LOX pathway including PLA۲ and ۵-LOX. Furthermore, we determined whether NAFLD progression pathway was delayed or reversed when zileuton (۱-[۱-(۱-benzothiophen-۲-yl)ethyl]-۱-hydroxyurea) was administrated. Results: Rat model for progression of NAFLD was well established as analyzed by liver transaminase activities, hematoxylin-eosin (HE) staining and NAS. The concentrations of substrates and products in AA/۵-LOX pathway were increased with the progression of NAFLD. mRNA and protein expression of PLA۲ and ۵-LOX were all enhanced. Moreover, administration of zileuton inhibited AA/۵-LOX pathway and reversed the increased transamine activities and NAS. Conclusion: AA/۵-LOX pathway promotes the progression of NAFLD, which can be reversed by zileuton.

Authors

Kuifen Ma

The First Affiliated Hospital, Zhejiang University;۷۹# Qingchun Road, Hangzhou ۳۱۰۰۰۳, China

Yihe Chen

The First Affiliated Hospital, Zhejiang University;۷۹# Qingchun Road, Hangzhou ۳۱۰۰۰۳, China

Xingguang Liang

The First Affiliated Hospital, Zhejiang University;۷۹# Qingchun Road, Hangzhou ۳۱۰۰۰۳, China

Jing Miao

The First Affiliated Hospital, Zhejiang University;۷۹# Qingchun Road, Hangzhou ۳۱۰۰۰۳, China

Qingwei Zhao

The First Affiliated Hospital, Zhejiang University;۷۹# Qingchun Road, Hangzhou ۳۱۰۰۰۳, China

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the ...
  • Verbeek J, Cassiman D, Lannoo M, Laleman W, van der ...
  • Gentile CL, Pagliassotti MJ. The role of fatty acids in ...
  • Shimomura Y, Takaki A, Wada N, Yasunaka T, Ikeda F, ...
  • Ayd N S, Atukeren PN, Akatay U, Uzun H, Altu ...
  • Nakamura Y, Kozuka M, Naniwa K, Takabayashi S, Torikai K, ...
  • Colak Y, Senates E, Ozturk O, Doganay HL, Coskunpinar E, ...
  • Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads ...
  • Xu XM, Deng JJ, Yuan GJ, Yang F, Guo HT, ...
  • Martinez-Clemente M, Claria J, Titos E. The ۵-lipoxygenase/leukotriene pathway in ...
  • Back M. Inhibitors of the ۵-lipoxygenase pathway in atherosclerosis. Curr ...
  • Cingi C, Muluk NB, Ipci K, Sahin E. Antileukotrienes in ...
  • Zhou GX, Ding XL, Wu SB, Zhang HF, Cao W, ...
  • Collin M, Rossi A, Cuzzocrea S, Patel NS, Di Paola ...
  • Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos ...
  • Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver ...
  • Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Faliva M, ...
  • Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Faliva M, ...
  • نمایش کامل مراجع